Asia - Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Market is Segmented by Drug (Januvia, Onglyza/Kombiglyze, Tradjenta, Nesina, Galvus, and Other Drugs) and Geography

Market Snapshot

Picture1
Study Period: 2018 - 2026
Base Year: 2020
CAGR: 0 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

  • Asia - Pacific has 60 % of diabetes mellitus patients, and it has seen a remarkable increase in diabetes patients over the past few decades. Prevalence of diabetes is increasing alongside the rise in the economic development of Asia.
  • The DPP-4 drugs are the new generation of oral anti-diabetes drugs that block the enzyme dipeptidyl peptidase-4 (DPP-4). They can be used to treat diabetes mellitus type-2.
  • Some of the factors, which contribute to the increased prevalence of diabetes are urbanization and modernization, dietary factor, smoking, and environmental pollution.

Scope of the Report

The Market is Segmented by Drugs (Januvia, Onglyza/Kombiglyze, Tradjenta, Nesina, Galvus, and Other Drugs) and Geography.

By Drug
Dipeptidyl peptidase - 4 (DPP-4) inhibitors (Market Size, Value and Volume, 2012-2024)
Januvia (Sitagliptin)
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina (Alogliptin)
Galvus (Vildagliptin)
Geography
Asia - Pacific
Japan (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
South Korea (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
China (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
India (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Australia (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Vietnam (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Malaysia (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Indonesia (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Philippines (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Thailand (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Rest of Asia - Pacific (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

Report scope can be customized per your requirements. Click here.

Key Market Trends

Tradjenta is Expected to Grow Exponentially and is Expected to Register a CAGR of approximately 13%

  • The Asia - Pacific dipeptide peptidase 4 (DPP-4) inhibitors market is expected to witness a high growth, during the forecast period (2019-2024), with a CAGR of 7.0% because of the launch of Eli Lilly’s Tradjenta in 2012.
  • DPP-4 are a once-daily medication used to control the glycemic level of blood. Januvia had the highest market value and growth in the historical period (2012-2018), but Tradjenta is expected to hold a major market share in the forecast period due to improved efficacy of the drug.      
  • The market for DPP-4 class of drugs includes Januvia, Tradjenta, Galvus, Nesina, and Onglyza among others. The demand for DPP-4 is expected to grow immensely in the near future due to drugs, such as Tradjenta and Januvia. The sales of Tradjenta has been increasing exponentially over the years. Tradjenta is gaining sales when compared to Januvia, due to its improved efficacy. 
Picture4

China Holds the Highest Market Share in Asia - Pacific in 2018.

  • The growing Asia - Pacific type-2 population promotes the growth of DPP-4 drugs. China accounts for the largest type-2 diabetic population among Asian countries, thus the sales of DPP-4 is high in the Country. 
  • The market studied in China accounted for USD 0.8 billion in 2018 and is expected to reach USD 1.2 billion by 2024. The Chinese Januvia market held the majority of the share in 2018. Also during the forecast period (2019-2024), the market studied is expected to grow at a high rate in China, while maintaining its dominance in the region. 
Picture3

Competitive Landscape

  • Merck held the highest market share in the DPP-4 market in 2018 and is expected to maintain its position until 2022. After that, it may witness a decline in the market share, due to the expected launch of a generic version of Sitagliptin in 2022.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Drivers

    3. 4.3 Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug

      1. 5.1.1 Dipeptidyl peptidase - 4 (DPP-4) inhibitors (Market Size, Value and Volume, 2012-2024)

        1. 5.1.1.1 Januvia (Sitagliptin)

        2. 5.1.1.2 Onglyza (Saxagliptin)

        3. 5.1.1.3 Tradjenta (Linagliptin)

        4. 5.1.1.4 Vipidia/Nesina (Alogliptin)

        5. 5.1.1.5 Galvus (Vildagliptin)

    2. 5.2 Geography

      1. 5.2.1 Asia - Pacific

        1. 5.2.1.1 Japan (Value and Volume, 2012-2024)

          1. 5.2.1.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.1.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        2. 5.2.1.2 South Korea (Value and Volume, 2012-2024)

          1. 5.2.1.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.1.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        3. 5.2.1.3 China (Value and Volume, 2012-2024)

          1. 5.2.1.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.1.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        4. 5.2.1.4 India (Value and Volume, 2012-2024)

          1. 5.2.1.4.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.1.4.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        5. 5.2.1.5 Australia (Value and Volume, 2012-2024)

          1. 5.2.1.5.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.1.5.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        6. 5.2.1.6 Vietnam (Value and Volume, 2012-2024)

          1. 5.2.1.6.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.1.6.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        7. 5.2.1.7 Malaysia (Value and Volume, 2012-2024)

          1. 5.2.1.7.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.1.7.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        8. 5.2.1.8 Indonesia (Value and Volume, 2012-2024)

          1. 5.2.1.8.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.1.8.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        9. 5.2.1.9 Philippines (Value and Volume, 2012-2024)

          1. 5.2.1.9.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.1.9.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        10. 5.2.1.10 Thailand (Value and Volume, 2012-2024)

          1. 5.2.1.10.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.1.10.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

        11. 5.2.1.11 Rest of Asia - Pacific (Value and Volume, 2012-2024)

          1. 5.2.1.11.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)

          2. 5.2.1.11.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

  6. 6. MARKET INDICATORS

    1. 6.1 Type-1 Diabetes population (2012 - 2024)

    2. 6.2 Type-2 Diabetes population (2012 - 2024)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 Company Profiles

      1. 7.1.1 Merck And Co.

      2. 7.1.2 AstraZeneca

      3. 7.1.3 Novartis

      4. 7.1.4 Takeda Pharmaceuticals

      5. 7.1.5 Eli Lilly

      6. 7.1.6 Boehringer Ingelheim

    2. 7.2 Company Share Analysis

      1. 7.2.1 Merck And Co.

      2. 7.2.2 AstraZeneca

      3. 7.2.3 Takeda Pharmaceuticals

      4. 7.2.4 Novartis

      5. 7.2.5 Eli Lilly & Boehringer Ingelheim

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The APAC Dipeptide Peptidase 4 (DPP-4) Inhibitors Market market is studied from 2018 - 2026.

The APAC Dipeptide Peptidase 4 (DPP-4) Inhibitors Market is growing at a CAGR of 0% over the next 5 years.

Merck, AstraZeneca, Novartis, Eli Lilly are the major companies operating in APAC Dipeptide Peptidase 4 (DPP-4) Inhibitors Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!